Jepsen Peter, West Joe
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, United Kingdom; NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom.
J Hepatol. 2021 May;74(5):1234-1239. doi: 10.1016/j.jhep.2020.12.029. Epub 2021 Jan 17.
Current guidelines from EASL recommend that most patients with cirrhosis are offered surveillance for hepatocellular carcinoma (HCC), but fewer patients than expected actually receive it. The recommendation is based on observational studies and simulations, not randomised trials. In this opinion piece we argue that a randomised trial of HCC surveillance vs. no surveillance is necessary and feasible, and we believe that clinician and patient participation in HCC surveillance would be better if it were based on trial results demonstrating its value.
欧洲肝脏研究学会（EASL）目前的指南建议，大多数肝硬化患者应接受肝细胞癌（HCC）监测，但实际接受监测的患者比预期的要少。该建议基于观察性研究和模拟分析，而非随机试验。在这篇观点文章中，我们认为有必要且可行开展一项关于HCC监测与不监测的随机试验，并且我们相信，如果基于能证明其价值的试验结果，临床医生和患者对HCC监测的参与度将会更高。
